Evidence map›Paper›PMID 40466719›Full record

ArticleInternal medicine journal2025

Intravenous administration of ferric derisomaltose is associated with a higher incidence of infusion reactions than ferric carboxymaltose, and unaffected by dilution volume.

Sarah Lucas, Ayushi Chauhan, Ciaran Hurley, Calvin Xu, Catherine Yu, Katrina Tan, Sarah Taylor, Mani Suleiman, Teresa Leung, Mayur Garg

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sarah LucasDepartment of Gastroenterology, Northern Health, Melbourne, Victoria, Australia.ORCID 0000-0002-4290-6631
Ayushi ChauhanDepartment of Gastroenterology, Northern Health, Melbourne, Victoria, Australia.
Ciaran HurleyDepartment of Gastroenterology, Northern Health, Melbourne, Victoria, Australia.
Calvin XuDepartment of Gastroenterology, Northern Health, Melbourne, Victoria, Australia.
Catherine YuDepartment of Gastroenterology, Northern Health, Melbourne, Victoria, Australia.
Katrina TanDepartment of Gastroenterology, Northern Health, Melbourne, Victoria, Australia.
Sarah TaylorDepartment of Gastroenterology, Northern Health, Melbourne, Victoria, Australia.
Mani SuleimanResearch Development and Governance Unit, Northern Health, Melbourne, Victoria, Australia.
Teresa LeungDepartment of Haematology, Northern Health, Melbourne, Victoria, Australia.ORCID 0000-0002-5549-682X
Mayur GargDepartment of Gastroenterology, Northern Health, Melbourne, Victoria, Australia.ORCID 0000-0002-9149-3589

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence of and risk factors for infusion-related reactions to intravenous iron formulations remains poorly characterised. This study aimed to compare the rates of infusion reactions in patients receiving ferric derisomaltose (FDI) compared to ferric carboxymaltose (FCM), as well as across different dilutions of FDI.

aimsTo compare the rates of infusion reactions in patients receiving ferric derisomaltose (FDI) compared to ferric carboxymaltose (FCM), as well as across different dilutions of FDI.

methodsThis was a single tertiary centre retrospective matched cohort study of patients who received FDI or FCM between January 2022 and May 2023. Reactions were classified as Fishbane or hypersensitivity and characterised by severity using the Ring and Messmer classification.

resultsA total of 660 patients (330 age- and sex-matched patients who received FDI and FCM, respectively) were included. Hypersensitivity reactions occurred in 34 of 330 (10.3%) patients receiving FDI infusions compared to eight of 330 (2.4%) patients receiving FCM (odds ratio (OR), 4.62 (95% confidence interval (CI), 2.10-9.78), P < 0.0001). All reactions to FCM and FDI were classified as mild to moderate except for one grade III reaction to FDI. There was no difference in the rate of reaction between patients receiving FDI diluted in 100 mL (18/165) compared to 250 mL (16/165) sodium chloride (OR, 1.14 (95% CI, 0.55-2.27), P = 0.86). A history of a reaction to an alternative iron formulation was associated with increased risk of infusion reactions (OR, 3.55 (95% CI, 0.67-18.97), P = 0.14) and increasing age was associated with reduced risk (OR, 0.96 (95% CI, 0.94-0.99), P = 0.02).

conclusionPatients receiving FDI had a significantly higher risk of mild infusion reactions compared to those receiving FCM, with no difference across different dilution volumes of FDI.

Indexed as

Drug HypersensitivityFerric CompoundsMaltoseAdultAgedFemaleHumansIncidenceInfusions, IntravenousMaleMiddle AgedRetrospective StudiesRisk Factorsferric carboxymaltoseFerric CompoundsMaltoseadverse drug reactionclinical pharmacologyferric carboxymaltoseferric derisomaltosegastroenterologyiron deficiency

Identifiers

PMID40466719
PMCPMC12347312

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.